iRhythm® Technologies to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
iRhythm Technologies (NASDAQ: IRTC) will participate in the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021, at 5:00 p.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iRhythm Technologies (NASDAQ: IRTC) will participate in the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021, at 5:00 p.m. Eastern Time. The event will feature a presentation by iRhythm's management, accessible via a live and archived webcast on their website. iRhythm is transforming cardiac arrhythmia diagnosis with wearable biosensors and advanced data analytics, improving patient care management. For more information, visit www.irhythmtech.com.
Details
News Market Reaction – IRTC
The recorded move for IRTC in the trading session of this news was +0.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Aug. 26, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming 19th Annual Morgan Stanley Global Healthcare Conference.
iRhythm’s management is scheduled to present on Thursday, September 9, 2021 at 5:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.
Investor Relations Contact
Leigh Salvo
(415) 937-5404
investors@irhythmtech.com
Media Contact
Morgan Mathis
(310) 528-6306
irhythm@highwirepr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.